{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:17:51Z","timestamp":1788808671508,"version":"build-2803163510"},"reference-count":36,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The prognostic nutritional index (PNI), a marker reflecting both nutritional and immune status, has been associated with prognosis in various malignancies. However, evidence in metastatic castration-resistant prostate cancer (mCRPC), particularly from non-Asian populations, remains limited. This study aimed to evaluate the prognostic value of baseline PNI and to develop a blood-based prognostic model in mCRPC patients treated with abiraterone acetate (AA), enzalutamide (ENZA), or cabazitaxel (CABA). Materials and Methods: This retrospective study included mCRPC patients treated with AA, ENZA, or CABA before or after docetaxel. PNI was calculated as: 10 \u00d7 serum albumin (g\/dL) + 0.005 \u00d7 total lymphocyte count (\/mm3). Patients were classified into low-PNI (\u226440.8) and high-PNI (&gt;40.8) groups using the median PNI value. Survival outcomes were analyzed using Kaplan\u2013Meier and Cox regression methods. Results: A total of 299 patients were analyzed: 133 (44.5%) received AA, 106 (35.5%) ENZA, and 60 (20.0%) CABA. Patients with high PNI had significantly longer median overall survival (OS; 30.2 vs. 12.6 months, p &lt; 0.001), radiologic progression-free survival (rPFS; 13.5 vs. 6.7 months, p &lt; 0.001), and PSA progression-free survival (PSA-PFS; 10.2 vs. 5.1 months, p &lt; 0.001). These associations remained significant across all treatment subgroups. In multivariate analysis, prostate surgery (HR: 0.6), high PNI (HR: 0.5), PSA response (HR: 0.5), and elevated ALP (HR: 1.6) were independent predictors of OS. A prognostic model incorporating PNI, alkaline phosphatase, and anemia stratified patients into four risk groups with distinct OS: 49.1, 30.8, 18.8, and 9.1 months, respectively. Conclusions: This is the largest study to date in a non-Asian mCRPC population showing that baseline PNI is a strong, independent prognostic factor for survival. The proposed blood-based tool may aid in clinical risk stratification, pending prospective validation.<\/jats:p>","DOI":"10.3390\/medicina61061105","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T07:38:15Z","timestamp":1750232295000},"page":"1105","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel"],"prefix":"10.3390","volume":"61","author":[{"given":"Hakan","family":"Taban","sequence":"first","affiliation":[{"name":"Medical Oncology Clinic, Medical Park Ankara Hospital, 06370 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Erman","sequence":"additional","affiliation":[{"name":"Department of Preventive Oncology, Hacettepe University Cancer Institute, 06230 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-9467","authenticated-orcid":false,"given":"Deniz Can","family":"Guven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Cancer Institute, 06230 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5460-4895","authenticated-orcid":false,"given":"Burak Yasin","family":"Aktas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Cancer Institute, 06230 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-3381","authenticated-orcid":false,"given":"Feride","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Medical Oncology Clinic, Samsun Education and Research Hospital, 55090 Samsun, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1465-4131","authenticated-orcid":false,"given":"Serkan","family":"Ya\u015far","sequence":"additional","affiliation":[{"name":"Medical Oncology Clinic, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, 06200 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3060-377X","authenticated-orcid":false,"given":"Hasan Cagri","family":"Yildirim","sequence":"additional","affiliation":[{"name":"Medical Oncology Clinic, Nigde Omer Halisdemir University Training and Research Hospital, 51200 Nigde, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9153-6921","authenticated-orcid":false,"given":"Ferit","family":"Aslan","sequence":"additional","affiliation":[{"name":"Medical Oncology Clinic, Medical Park Ankara Hospital, 06370 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-1049","authenticated-orcid":false,"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Cancer Institute, 06230 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","unstructured":"National Comprehensive Cancer Network (2025, April 20). Prostate Cancer (Version 2.2025). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdfhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer","volume":"381","author":"Sternberg","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Conteduca, V., Mosca, A., Brighi, N., de Giorgi, U., and Rescigno, P. (2021). New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. Cells, 10.","DOI":"10.3390\/cells10010193"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Chang, L.W., Hung, S.C., Li, J.R., Chiu, K.Y., Yang, C.K., Chen, C.S., Lu, K., Chen, C.C., Wang, S.C., and Lin, C.Y. (2020). Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.601513"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.acuroe.2021.12.005","article-title":"Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide","volume":"46","year":"2022","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas (Engl. Ed.)"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/pros.23381","article-title":"Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone","volume":"77","author":"Fan","year":"2017","journal-title":"Prostate"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pros.23465","article-title":"Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients","volume":"78","author":"Fan","year":"2018","journal-title":"Prostate"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41391-020-0209-3","article-title":"Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A meta-analysis","volume":"23","author":"Guan","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Qian, L., Liu, T., Ding, J.S., Zhang, X., Song, M.M., Wang, Z.W., Ge, Y.Z., Hu, C.L., and Li, X.R. (2021). Prevalence and Prognostic Value of Malnutrition Among Elderly Cancer Patients Using Three Scoring Systems. Front. Nutr., 8.","DOI":"10.3389\/fnut.2021.738550"},{"key":"ref_14","first-page":"1001","article-title":"Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients","volume":"85","author":"Onodera","year":"1984","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s10147-019-01461-7","article-title":"Clinical significance of prognostic nutritional index (PNI) in malignant melanoma","volume":"24","author":"Mirili","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Luan, C.W., Tsai, Y.T., Yang, H.Y., Chen, K.Y., Chen, P.H., and Chou, H.H. (2021). Pretreatment prognostic nutritional index as a prognostic marker in head and neck cancer: A systematic review and meta-analysis. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-96598-9"},{"key":"ref_17","first-page":"5636","article-title":"Prognostic nutritional index as a prognostic factor in lung cancer patients receiving chemotherapy: A systematic review and meta-analysis","volume":"25","author":"Zhang","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1177\/1078155219883004","article-title":"The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer","volume":"26","author":"Yasar","year":"2020","journal-title":"J. Oncol. Pharm. Pr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijsu.2019.05.018","article-title":"The prognostic nutritional index is prognostic factor of gynecological cancer: A systematic review and meta-analysis","volume":"67","author":"Wang","year":"2019","journal-title":"Int. J. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1111\/ajco.13328","article-title":"The prognostic value of the prognostic nutritional index in patients with metastatic colorectal cancer","volume":"16","author":"Ucar","year":"2020","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00520-024-08572-6","article-title":"The prognostic value of immune-nutritional status in metastatic colorectal cancer: Prognostic Nutritional Index (PNI)","volume":"32","author":"Keskinkilic","year":"2024","journal-title":"Support. Care Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Tobing, E., Tansol, C., Tania, C., and Sihombing, A.T. (2024). Prognostic Nutritional Index (PNI) as Independent Predictor of Poor Survival in Prostate Cancer: A Systematic Review and Meta-Analysis. Clin. Genitourin. Cancer, 22.","DOI":"10.1016\/j.clgc.2024.102142"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41391-023-00689-9","article-title":"Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: A systematic review and meta-analysis","volume":"27","author":"Zheng","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy","volume":"368","author":"Ryan","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in Men with Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"Oudard","year":"2010","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bjc.2014.90","article-title":"Cancer and systemic inflammation: Treat the tumour and treat the host","volume":"110","author":"Roxburgh","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gupta, D., and Lis, C.G. (2010). Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr. J., 9.","DOI":"10.1186\/1475-2891-9-69"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2217\/bmm-2020-0674","article-title":"Lower prognostic nutritional index is associated with poorer survival in patients receiving immune checkpoint inhibitors","volume":"15","author":"Guven","year":"2021","journal-title":"Biomark. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1007\/s12094-021-02560-6","article-title":"PILE: A candidate prognostic score in cancer patients treated with immunotherapy","volume":"23","author":"Guven","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Li, B., Lu, Z., Wang, S., Hou, J., Xia, G., Li, H., Yin, B., and Lu, W. (2020). Pretreatment elevated prognostic nutritional index predicts a favorable prognosis in patients with prostate cancer. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06879-1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.2147\/CMAR.S333190","article-title":"Prognostic Significance of Preoperative Prognostic Nutritional Index for Overall Survival and Postoperative Complications in Esophageal Cancer Patients","volume":"13","author":"Qi","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/pros.24876","article-title":"Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization","volume":"85","author":"Hacioglu","year":"2025","journal-title":"Prostate"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2016.03.017","article-title":"The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer","volume":"70","author":"Evans","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdv594","article-title":"A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel","volume":"27","author":"Chi","year":"2016","journal-title":"Ann. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/6\/1105\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:54:13Z","timestamp":1760032453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/6\/1105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["medicina61061105"],"URL":"https:\/\/doi.org\/10.3390\/medicina61061105","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]}}}